Skye Bioscience, Inc. (SKYE)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
1.55 USD
-0.04
(-2.516%) ⇩
(Oct. 16, 2026, 12:29 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:21 a.m. EDT
The investment case for Skye Bioscience is currently broken by a catastrophic multi-year decline and deteriorating operational reality. While the company possesses a massive theoretical upside based on analyst targets, the market has priced in a severe failure of its core assets, evidenced by the stock trading at roughly 99% below its five-year average and a recent 60% single-day drop following a failed obesity drug trial. The balance sheet is fragile, with negative book value and significant cash burn, forcing the company to delist to a lower tier exchange due to equity shortfalls. There is no dividend to provide income, and the recent news cycle confirms that the pipeline is struggling to deliver results. The heavy put options activity reflects a speculative community that has abandoned the stock, viewing it as a high-risk liability rather than a turnaround opportunity. Until there is concrete proof of a successful clinical milestone and a stabilized balance sheet, the risk of permanent capital loss outweighs any potential recovery. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.634290 |
| MSTL | 0.697118 |
| AutoARIMA | 0.705123 |
| AutoETS | 0.710713 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 38.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.047 |
| Excess Kurtosis | -1.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 6,862,897 |
| Forward P/E | -0.21 |
| Beta | 2.86 |
| Previous Name | Emerald Bioscience Inc. |
| Website | https://skyebioscience.com |
As of Oct. 10, 2026, 6:21 a.m. EDT: Speculators are overwhelmingly positioned for downside protection rather than upside speculation. Put volume and open interest significantly exceed call volume across all expirations, with deep in-the-money puts holding substantial open interest while out-of-the-money calls are virtually nonexistent. This heavy put positioning suggests a consensus view of continued weakness or a 'bag holder' scenario where investors are hedging against further declines rather than betting on a recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.85597825 |
| Address1 | 11,250 El Camino Real |
| Address2 | Suite 100 |
| All Time High | 15,500.0 |
| All Time Low | 1.5 |
| Ask | 1.83 |
| Ask Size | 4 |
| Average Daily Volume10 Day | 29,810 |
| Average Daily Volume3 Month | 89,539 |
| Average Volume | 89,539 |
| Average Volume10Days | 29,810 |
| Beta | 2.859 |
| Bid | 1.16 |
| Bid Size | 2 |
| Book Value | -0.113 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.55 |
| Current Ratio | 0.95 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.6 |
| Day Low | 1.55 |
| Display Name | Skye Bioscience |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,773,174,600 |
| Earnings Call Timestamp Start | 1,773,174,600 |
| Earnings Timestamp End | 1,794,250,800 |
| Earnings Timestamp Start | 1,794,250,800 |
| Ebitda | -47,366,696 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.06 |
| Enterprise Value | -2,845,388 |
| Eps Current Year | -5.04 |
| Eps Forward | -7.4 |
| Eps Trailing Twelve Months | -10.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.20042 |
| Fifty Day Average Change | -0.65041995 |
| Fifty Day Average Change Percent | -0.295589 |
| Fifty Two Week Change Percent | -85.597824 |
| Fifty Two Week High | 13.28 |
| Fifty Two Week High Change | -11.73 |
| Fifty Two Week High Change Percent | -0.88328314 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 0.049999952 |
| Fifty Two Week Low Change Percent | 0.0333333 |
| Fifty Two Week Range | 1.5 - 13.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,420,554,600,000 |
| Float Shares | 2,986,955 |
| Forward Eps | -7.4 |
| Forward P E | -0.20945945 |
| Free Cashflow | -18,710,042 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 2 |
| Fullday Change | -0.04000008 |
| Fullday Change Percent | -2.5157282 |
| Fullday Price | 1.55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0424 |
| Held Percent Institutions | 0.4017 |
| Implied Shares Outstanding | 4,427,676 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-04-11 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,787,529,600 |
| Last Split Factor | 1:8 |
| Long Business Summary | Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California. |
| Long Name | Skye Bioscience, Inc. |
| Market | us_market |
| Market Cap | 6,862,897 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_266974060 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -50,492,576 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,969,816 |
| Number Of Analyst Opinions | 4 |
| Open | 1.6 |
| Operating Cashflow | -38,810,452 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 410 0266 |
| Prev Name | Emerald Bioscience Inc. |
| Previous Close | 1.59 |
| Price Eps Current Year | -0.30753967 |
| Price Hint | 4 |
| Price To Book | -13.716814 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.873 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.04000008 |
| Regular Market Change Percent | -2.5157282 |
| Regular Market Day High | 1.6 |
| Regular Market Day Low | 1.55 |
| Regular Market Day Range | 1.55 - 1.6 |
| Regular Market Open | 1.6 |
| Regular Market Previous Close | 1.59 |
| Regular Market Price | 1.55 |
| Regular Market Time | 1,792,168,140 |
| Regular Market Volume | 12,213 |
| Return On Assets | -0.95056 |
| Return On Equity | -2.33873 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,427,676 |
| Shares Percent Shares Out | 0.0334 |
| Shares Short | 147,954 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 128,781 |
| Short Name | Skye Bioscience, Inc. |
| Short Percent Of Float | 0.0467 |
| Short Ratio | 1.72 |
| Source Interval | 15 |
| State | CA |
| Symbol | SKYE |
| Target High Price | 160.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 68.0 |
| Target Median Price | 48.0 |
| Total Cash | 10,064,141 |
| Total Cash Per Share | 2.273 |
| Total Debt | 178,746 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.188505 |
| Two Hundred Day Average Change | -3.6385052 |
| Two Hundred Day Average Change Percent | -0.7012627 |
| Type Disp | Equity |
| Volume | 12,213 |
| Website | https://skyebioscience.com |
| Zip | 92,130 |